Trending...
- Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion
- Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
- GDE Tree Services Expands Operations into Sydney, NSW
LANGHORNE, Pa. ~ Techdow USA Inc., a vertically integrated generic injectables company, has announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.
Darren Alkins, Chief Executive Officer of Techdow USA, said "We are excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin. Our U.S. and global networks will help ensure reliable Enoxaparin supply, while offering competitive pricing."
The launch of Enoxaparin will compliment Techdow USA's existing Heparin Sodium injection business which was launched in 2022. According to IQVIA Health for the 12 months ending December 2022, Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million.
Techdow USA is among the fastest growing companies in the US generic pharmaceutical industry specializing in the sale of generic injectable pharmaceuticals and continues to work to expand their product portfolio and pipeline to better serve patient and customer needs. To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For more information visit www.techdowusa.com.*Lovenox® is a registered trademark of Sanofi-Aventis U.S. LLC
More on The PennZone
Techdow USA Inc., a growing market leader in the generic injectables industry, has announced that its product Enoxaparin Sodium (Preservative Free) in Prefilled Syringes has been approved by the FDA for use in the U.S market. Darren Alkins, Chief Executive Officer of Techdow USA expressed his excitement about bringing this critical product to institutions, retail and other networks that need a safe, affordable and reliable source of Enoxaparin with competitive pricing options available through their U.S and global networks as well as being a long term reliable resource for the marketplace .
The launch of Enoxaparin compliments Techdow USA's existing Heparin Sodium injection business which was launched in 2022 with IQVIA Health reporting US brand and generic sales for this product at approximately $550 million for the 12 months ending December 2022 .
Techdow USA is continuing its efforts to expand its product portfolio and pipeline to better serve patient and customer needs while also being one of the fastest growing companies in the US generic pharmaceutical industry specializing in selling generic injectable pharmaceuticals . To report SUSPECTED ADVERSE REACTIONS contact Hepalink USA , Inc./Techdow USA , Inc . at 1 - 888 - 355 - 1375 or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch . For more information visit www . techdowusa . com * Lovenox® is a registered trademark of Sanofi - Aventis U . S . LLC
Darren Alkins, Chief Executive Officer of Techdow USA, said "We are excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin. Our U.S. and global networks will help ensure reliable Enoxaparin supply, while offering competitive pricing."
The launch of Enoxaparin will compliment Techdow USA's existing Heparin Sodium injection business which was launched in 2022. According to IQVIA Health for the 12 months ending December 2022, Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million.
Techdow USA is among the fastest growing companies in the US generic pharmaceutical industry specializing in the sale of generic injectable pharmaceuticals and continues to work to expand their product portfolio and pipeline to better serve patient and customer needs. To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For more information visit www.techdowusa.com.*Lovenox® is a registered trademark of Sanofi-Aventis U.S. LLC
More on The PennZone
- Deborah E. Jones Introduces Emotional Sovereignty, a Powerful New Book on Emotional Mastery, Resilience, and Intentional Living
- New Research Identifies "The Busy Effect": 89% of Americans Want a Laid-Back Vacation — Only 15% Actually Achieve It
- Alchemy 43 Appoints Shane Smith as CEO to Drive Operational Performance and Scalable Growth
- Best Spiritual Healing, Meditation & Retreats in Sedona — Rise Meditation Helps You Find and Book Transformational Experiences
- $16 Billion Market by 2034 in Underwater Drones Presents Huge Opportunity for AI-Powered Autonomous Vehicle Serving Defense & Commercial Customers
Techdow USA Inc., a growing market leader in the generic injectables industry, has announced that its product Enoxaparin Sodium (Preservative Free) in Prefilled Syringes has been approved by the FDA for use in the U.S market. Darren Alkins, Chief Executive Officer of Techdow USA expressed his excitement about bringing this critical product to institutions, retail and other networks that need a safe, affordable and reliable source of Enoxaparin with competitive pricing options available through their U.S and global networks as well as being a long term reliable resource for the marketplace .
The launch of Enoxaparin compliments Techdow USA's existing Heparin Sodium injection business which was launched in 2022 with IQVIA Health reporting US brand and generic sales for this product at approximately $550 million for the 12 months ending December 2022 .
Techdow USA is continuing its efforts to expand its product portfolio and pipeline to better serve patient and customer needs while also being one of the fastest growing companies in the US generic pharmaceutical industry specializing in selling generic injectable pharmaceuticals . To report SUSPECTED ADVERSE REACTIONS contact Hepalink USA , Inc./Techdow USA , Inc . at 1 - 888 - 355 - 1375 or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch . For more information visit www . techdowusa . com * Lovenox® is a registered trademark of Sanofi - Aventis U . S . LLC
Filed Under: Business
0 Comments
Latest on The PennZone
- Boston Industrial Solutions Expands Its Industry-Leading UV Ink Portfolio with the Launch of a Matte Ink - Natron® UVPZ
- The Eichelberger Performing Arts Center Announces 6 Youth Summer Camps
- Feldman Shepherd's Ezra Wohlgelernter Honored by SeniorLAW Center for Two Decades of Service
- Century Fasteners Corp. Exhibiting at 2026 MRO Americas Show – April 21-23, 2026 – Booth #2257
- Blue Sparrow Coffee named Best Matcha in Westword's Best of Denver 2026
- Ocean County College Introduces Pathways to Simplify the Student Journey and Strengthen Career Connections
- Kiko Nation Expands to Apple App Store, Achieving Full Mobile Deployment for Livestock Digital Registry Platform
- The Lawyers' Marketer Launches Claude AI Implementation Service for Law Firms
- Certified Trading Card Association and Collectors MD Launch Healthy Hobby Initiative
- Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion
- L2 Aviation Earns FAA STC for Thales AVIATOR 200S for Boeing 777
- Pittsburgh-Based Phoinix Events Selected as Vendor for NFL Draft
- FinIQ Edu Launches High-Impact Workshop Vertical to Close the Workplace Benefits Gap—Drives 82% Surge in 401(k) Participation Intent
- HousingWire launches Mortgage Rankings, bringing a data-driven benchmark to originator performance
- J&J Exterminating Reminds Residents to prepare for Termite Swarm Season
- Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
- Tyler G. Hicks' Encyclopedia of Wealth Building Secrets Released in a Powerful New Edition
- Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
- New Book Gives Technology Leaders the Blueprint to Drive Real, Lasting Impact
- IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i